A “no-biopsy” approach to diagnosing celiac disease
Date Added:
October 25, 2022
Journal/Publication:
Journal of Family Practice
Publisher:
Frontline Medical Communications
Publication Date:
October 1, 2022
Issue:
8
Volume:
71
Pages:
359-361
Type:
Meta-analyses, Reviews, and Guidelines
Format:
Article
DOI (1):
10.12788/jfp.0485
Abstract
PRACTICE CHANGER
CONSIDER A “NO-BIOPSY” APPROACH BY EVALUATING SERUM IMMUNOGLOBULIN (IG) A ANTI-TISSUE TRANSGLUTAMINASE (TTG-IGA) ANTIBODY TITERS IN ADULT PATIENTS WHO PRESENT WITH SYMPTOMS CONCERNING FOR CELIAC DISEASE (CD). AN INCREASE OF ≥ 10 TIMES THE UPPER LIMIT OF NORMAL (ULN) FOR TTG-IGA HAS A POSITIVE PREDICTIVE VALUE (PPV) OF ≥ 95% FOR DIAGNOSING CD WHEN COMPARED WITH ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH DUODENAL BIOPSY—THE CURRENT GOLD STANDARD.
Text Availability
Free full text
RPR Commentary
This antibody test is almost as good as a biopsy for diagnosing celiac disease. James W. Mold, MD, MPH